PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.270
+0.110 (3.48%)
At close: Jun 6, 2025, 4:00 PM
3.400
+0.130 (3.98%)
After-hours: Jun 6, 2025, 7:59 PM EDT
PolyPid Employees
As of December 31, 2024, PolyPid had 60 total employees, including 57 full-time and 3 part-time employees. The number of employees decreased by 2 or -3.23% compared to the previous year.
Employees
60
Change (1Y)
-2
Growth (1Y)
-3.23%
Revenue / Employee
n/a
Profits / Employee
-$514,033
Market Cap
33.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PYPD News
- 1 day ago - PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - GlobeNewsWire
- 8 days ago - PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout - GlobeNewsWire
- 18 days ago - PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - GlobeNewsWire
- 24 days ago - PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewsWire
- 6 weeks ago - PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 3 months ago - PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - GlobeNewsWire